Aaranya Biosciences Private Limited is based in Headquarter in Hyderabad and Research Facility at Biotech Park, Chennai. We focus on early discovery, which includes SAR support, medicinal chemistry, and optimization of drug-ability. Importantly, we ensure that the optimization of ADME properties of the drug candidates is integrated with all other essential properties to achieve an optimal balance between ADME, pharmacological and toxicological properties.
Our established objective is to connect people from varied industry segments; collaborate and facilitate to create value to clients through invention,discovery, and commercializing the product/molecule. Founded in 2013, Aaranya Biosciences leverages on its experienced manpower and state-of-art infrastructure to provide high quality R&D services across chemistry, biology, DMPK, toxicology and pharmacology.
We believe that continuous innovation means to investigate, create, evaluate, activate and celebrate research and discovery services.
Clients get a two-way benefit by collaborating with us. Our business models present transparenu pricing and an assurance on greater reachability in the market. We offer budget friendly research and discovery services through the latest operational structure and project specific alliances..
|Hands on Training in Food Technology by Aaranya Biosciences Private Limited -Biotechnology Students of Anna University|
|Hands on Training in Food Technology by Aaranya Biosciences Private Limited -Biotechnology Students of Sivakasi|
|Hands on Training,Internship by Aaranya Biosciences Private Limited -Biotechnology Students of Chattigarh|
We offer computational chemistry & computational biology services to academic and industrial researchers involved in drug discovery and development
We provide bio-analysis supporting all phases of drug development and non-GLP rapid discovery phase bio-analysis for discovery support. Our capabilities include proprietary method development, validation, transfer, and high throughput sample analysis.
Medicinal chemistry is one of our core strengths. It includes programs covering various therapeutic areas including metabolic diseases, oncology, CNS diseases, inflammation,pain, dermatology and infectious diseases.
We can help you with hands-on creation of liquid types or dry types of drug formulations, provide you with access to centers of expertise that provide unique new technologies, assist you with patent and literature
We offer the largest array of enzyme assays. We have the expertise to leverage on Cell based specialized assays using cell lines, primary cells to study the cell interactions.
We have time tested business models for each pharma and bio industry clients' specific needs in the pharma and life sciences industries. Our flexible and strategic models combine our location advantage and proven competencies. With
We offer a full range of invivo and invitro pharmacokinetic studies for compounds and identification of metabolites in rodents (rats, mice, minipigs, dogs, sheep, rabbits, hamster, guinea pigs) and large animals (Beagle dogs and cats).
Integrated Discovery Services
We run successful and fully integrated programs for clients at our state-of-art laboratory. Our clients include pharmaceutical companies, biotechnology firms, cosmetics animal health.
From stand-alone discovery support to full development program, we can provide custom and need-specific solutions that include physico-chemical profiling,degration, stability study, optimization of existing formulations, life cycle management and development.
We are a drug discovery company with a track record of early drug candidate delivery. By leveraging on innovative proprietary technologies, we could reach the industry average drug discovery timelines of 30%.
Toxicity and Safety Pharmacology
The in vivo facility at Aaranya Biosciences offers a full range of non-GLP safety pharmacology and toxicology evaluations. We deal in diseases relating to cardiovascular, CNS, pulmonary, renal, gastrointestinal, and autonomic nervous system safety pharmacology
In recent times a rise in the incidence of Infectious or Communicable Diseases has been observed in many parts of the world. The pathogens have become resilient, drugs with multi variant mechanisms are being designed